Skip to main content
. Author manuscript; available in PMC: 2020 Aug 10.
Published in final edited form as: Ann Lymphoma. 2020 Mar;4:1. doi: 10.21037/aol.2019.12.01

Figure 2.

Figure 2

CDK4/6 inhibitors and model of imbalanced gene expression in cell cycle. (A) Three oral small-molecule reversible CDK4/6 inhibitors that have been approved by the FDA for breast cancer treatment. (B) Model for reversible induction of prolonged cell cycle arrest in early G1 (pG1) by inhibition of CDK4/CDK6 with palbociclib and synchronous S phase entry after the release from pG1 (pG1-S). Rb, retinoblastoma protein; CDK, cyclin-dependent kinase.